local_hospital

Semmelweis University

Address
lock Available on a paid plan

Gastroenterology and Inflammatory Bowel Disease

At Semmelweis University, a major share of clinical research focuses on digestive system diseases, especially Crohn’s disease and ulcerative colitis. These studies are largely designed to test new therapies and better understand how to achieve and maintain disease control in people living with chronic intestinal inflammation.

  • Research on Crohn’s disease and ulcerative colitis is prominent across adult and pediatric populations.
  • Trials also explore related conditions such as short bowel syndrome and Clostridioides difficile infection.
  • Several studies aim to improve remission rates, symptom control, and long-term treatment effectiveness.

The site’s activity in this field reflects a strong interest in advancing both new treatment options and ongoing care strategies for chronic gastrointestinal disease.

Cardiovascular Disease and Metabolic Health

Clinical trials at this site also cover a broad range of cardiovascular diseases and nutritional and metabolic diseases, including heart failure, coronary artery disease, stroke, hypertension, and obesity. The research often seeks to evaluate treatment effectiveness, reduce risk of future events, and improve long-term outcomes in high-risk patients.

  • Studies address heart failure, myocardial infarction, and atrial fibrillation.
  • Metabolic research includes hyperlipidemia, hypercholesterolemia, and type 2 diabetes.
  • Some trials focus on preventing complications such as recurrent stroke or worsening cardiac function.

This cardiovascular portfolio highlights a strong emphasis on prevention, risk reduction, and improving care for chronic heart and metabolic conditions.

Oncology and Hematologic Malignancies

The research landscape includes extensive work in neoplasms, with studies in lung cancer, breast cancer, prostate cancer, colorectal cancer, and multiple blood cancers such as leukemia, lymphoma, and multiple myeloma. These trials are primarily aimed at testing new cancer therapies and improving disease control in both solid and blood-related tumors.

  • Common areas include non-small cell lung cancer, small cell lung cancer, and metastatic solid tumors.
  • Blood cancer studies cover acute myeloid leukemia, diffuse large B-cell lymphoma, and myelofibrosis.
  • Some projects focus on improving survival, slowing progression, or supporting treatment after standard care.

Semmelweis University appears to be an active site for oncology research spanning both common cancers and more specialized rare malignancies.

Ophthalmology and Vision Disorders

Another important area of research involves eye diseases, especially diabetic macular edema, age-related macular degeneration, diabetic retinopathy, and other retinal conditions. These trials generally aim to improve vision-related outcomes, compare treatment effectiveness, and assess longer-term eye health.

  • Studies include wet age-related macular degeneration and geographic atrophy.
  • Research also addresses macular edema linked to retinal vein occlusion and diabetes.
  • The goal is often to preserve vision and evaluate whether new approaches can offer better disease control.

This field shows a clear focus on helping patients with chronic retinal disease maintain sight and daily function.

Neurology and Mental Health

Clinical trials in nervous system diseases and psychiatry and psychology cover conditions such as epilepsy, migraine, multiple sclerosis, Alzheimer’s disease, schizophrenia, and major depressive disorder. The purpose of this research is often to improve symptom relief, support long-term management, and evaluate new treatment options for complex neurological and psychiatric illnesses.

  • Epilepsy studies include focal seizures and generalized seizures.
  • Other work examines migraine prevention, multiple sclerosis, and cognitive decline.
  • Psychiatric trials explore treatment options for depression and schizophrenia.

The breadth of this research shows a strong commitment to disorders that affect thinking, movement, mood, and quality of life.

Pediatrics, Rare Diseases, and Immune Disorders

The Gyermekgyogyaszati Klinika supports a wide range of pediatric and specialty studies involving congenital diseases, immune system diseases, musculoskeletal disorders, and rare inherited conditions. Many trials are designed to test new therapies in children, improve safety and tolerability, or refine treatment approaches for uncommon but serious illnesses.

  • Research includes biliary atresia, spinal muscular atrophy, and juvenile idiopathic arthritis.
  • Immune-focused studies address myasthenia gravis, immune thrombocytopenia, and systemic lupus erythematosus.
  • Additional work covers rare genetic and developmental disorders in younger patients.

This pediatric portfolio reflects a broad effort to bring innovative care to children with complex, chronic, and often rare diseases.

Respiratory, Renal, and Infectious Disease Research

Trials at Semmelweis University also extend into respiratory tract diseases, kidney disease, and bacterial infections. These studies are generally focused on improving treatment effectiveness, preventing complications, and supporting patients with severe or long-lasting illness.

  • Respiratory research includes asthma, COPD, bronchiectasis, and pulmonary fibrosis.
  • Renal studies address chronic kidney disease, IgA nephropathy, and transplant-related issues.
  • Infectious disease work includes sepsis, pneumonia, and serious gram-negative infections.

These programs show a practical focus on conditions that can lead to hospitalization, long-term disability, or major complications if not managed effectively.

Site Overview

assignment
472
connected trials
corporate_fare
171
sponsors
science
547
IMPs

Activity Indicator

Last 6 months

50
Trials started
-23% vs previous period.
65
Trials started 6–12 months ago
472
Total trials linked
Highly Active
trending_downDeclining-23%
11
8
14
8
7
2
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 5 of 29 therapeutic areas and 15 of 547 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 521 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
245
Sponsors (total)
171
Active sponsors
107

Sponsor Network

Top 107 by active trials.

lock +106 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +64 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 332 other sites in Hungary

description
Trial volume
472
Outperforms 100% of sites
public
Therapeutic diversity
29areas
Outperforms 100% of sites
groups
Sponsor diversity
171sponsors
Outperforms 100% of sites

Therapeutic Area Benchmark — Hungary

Select a therapeutic area to compare against other sites in Hungary.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Hungary

Market Share

Country: Hungary

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Semmelweis University

lock Showing 1 of 472 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
(21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancerBayer AG, Bayer Consumer Care AGPhase IIINot RecruitingOct 2023

IMP list

lock Showing 1 of 547 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Pembrolizumab21Unknown2019-06-262026-01-21

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.